# TRANSFORMATIONAL EPICENTER

---

## Ibogaine Research Summary

### Clinical Evidence, Safety Protocols & Therapeutic Applications

---

**Document Classification:** Confidential -- Investor Data Room
**Document Number:** 18 of 21
**Prepared For:** Prospective Investors & Strategic Partners
**Date:** January 2026
**Version:** 1.0

---

> *This document summarizes the current state of ibogaine clinical research, safety
> evidence, and Transformational Epicenter's evidence-based protocol design. All
> referenced studies are cited in the References section.*

---

## Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Mechanism of Action](#2-mechanism-of-action)
3. [Clinical Evidence](#3-clinical-evidence)
4. [Safety & Cardiac Considerations](#4-safety--cardiac-considerations)
5. [TE's Ibogaine Protocol](#5-tes-ibogaine-protocol)
6. [Ibogaine Treatment Center Comparison](#6-ibogaine-treatment-center-comparison)
7. [Regulatory Landscape](#7-regulatory-landscape)
8. [Market Opportunity](#8-market-opportunity)
9. [References](#9-references)

---

## 1. Executive Summary

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the African shrub *Tabernanthe iboga*. Over the past two decades, a growing body of clinical and observational evidence has demonstrated ibogaine's remarkable ability to interrupt opioid addiction, alleviate treatment-resistant depression, and catalyze profound psychological healing.

**Key findings from the clinical literature:**

- **60-80% addiction interruption rates** in opioid-dependent patients, sustained at 12-month follow-up (Brown & Alper, 2018)
- **Significant reductions** in opioid withdrawal symptoms within 24-48 hours of administration
- **Neuroplasticity enhancement** through BDNF upregulation, enabling lasting behavioral change
- **Multi-receptor pharmacology** that addresses addiction across multiple neurochemical pathways simultaneously

The global psychedelic therapy market is valued at **$3-5 billion** with a projected **15-20% CAGR** through 2030. Ibogaine occupies a unique position within this market as the only known compound capable of single-dose addiction interruption. The State of Texas allocated **$50 million** for ibogaine clinical research in 2025, signaling mainstream institutional acceptance.

Transformational Epicenter is positioned to deliver ibogaine-assisted therapy within the most medically rigorous and luxuriously appointed setting available globally, integrating hospital-grade cardiac monitoring, board-certified physician oversight, and comprehensive bio-optimization protocols that no competitor currently matches.

---

## 2. Mechanism of Action

Ibogaine's therapeutic efficacy derives from its unique multi-target pharmacological profile. Unlike conventional addiction medications that act on a single receptor system, ibogaine simultaneously modulates multiple neurotransmitter pathways implicated in addiction, mood regulation, and neuroplasticity.

### 2.1 NMDA Receptor Modulation

Ibogaine acts as a non-competitive antagonist at NMDA (N-methyl-D-aspartate) glutamate receptors. This mechanism is believed to play a central role in:

- **Resetting tolerance** to opioids and other substances
- **Disrupting conditioned drug-seeking behavior** by modulating glutamatergic signaling in the prefrontal cortex and nucleus accumbens
- **Reducing excitotoxicity** associated with acute withdrawal states
- **Enhancing synaptic plasticity** to support the formation of new behavioral patterns

The NMDA receptor interaction is pharmacologically distinct from ketamine's mechanism, producing longer-lasting effects through downstream gene expression changes rather than acute receptor blockade alone.

### 2.2 Serotonin System Interaction

Ibogaine and its long-acting metabolite noribogaine interact with the serotonin (5-HT) system at multiple points:

- **5-HT2A receptor agonism** -- responsible for the visionary and psychologically introspective effects that facilitate trauma processing
- **Serotonin transporter (SERT) inhibition** -- noribogaine functions as a serotonin reuptake inhibitor, providing sustained antidepressant effects for weeks to months following a single administration
- **5-HT3 receptor antagonism** -- contributes to anti-emetic effects and mood stabilization during the acute phase

This multi-site serotonergic activity is believed to underlie the sustained improvements in mood and well-being reported by patients for months following treatment.

### 2.3 Opioid Receptor Resetting

Ibogaine demonstrates affinity for mu, delta, and kappa opioid receptors:

- **Mu-opioid receptor modulation** -- reduces withdrawal symptoms and cravings without producing the reinforcing effects associated with opioid agonists
- **Kappa-opioid receptor interaction** -- contributes to the dissociative and introspective experience, facilitating psychological processing of addiction patterns
- **Opioid system "reset"** -- patients consistently report a dramatic reduction or elimination of physical withdrawal symptoms within 24-48 hours

### 2.4 Neurotrophin Upregulation

Perhaps the most significant long-term mechanism involves ibogaine's effect on neurotrophic factors:

- **BDNF (Brain-Derived Neurotrophic Factor)** -- ibogaine and noribogaine increase BDNF expression, promoting neurogenesis, synaptogenesis, and neural circuit remodeling
- **GDNF (Glial Cell Line-Derived Neurotrophic Factor)** -- upregulation of GDNF in the ventral tegmental area (VTA) is associated with long-term reductions in drug-seeking behavior
- **Neuroplasticity window** -- the 30-90 day period following ibogaine administration represents an enhanced window for therapeutic integration and behavioral change

### 2.5 Dopamine Pathway Modulation

Ibogaine modulates dopaminergic signaling in the mesolimbic reward pathway:

- Reduces the sensitized dopamine response associated with addictive substances
- Normalizes dopamine receptor density altered by chronic substance use
- Facilitates a recalibration of the reward system toward natural reinforcers

> **Summary:** Ibogaine's multi-target pharmacology -- simultaneously addressing NMDA, serotonin, opioid, dopamine, and neurotrophic systems -- explains its unique ability to produce rapid, sustained addiction interruption from a single administration. No other known compound demonstrates this breadth of action.

---

## 3. Clinical Evidence

### 3.1 Brown & Alper (2018) -- Addiction Interruption

**Study:** "Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes"
**Design:** Systematic review and meta-analysis of available clinical data
**Key Findings:**

| Metric | Result |
|--------|--------|
| **Addiction interruption rate** | 60-80% |
| **Withdrawal symptom reduction** | Significant within 24-48 hours |
| **Sustained abstinence (12 months)** | 50-60% of responders |
| **Craving reduction** | Clinically significant across all subjects |

This study represents the most comprehensive review of ibogaine's efficacy for opioid use disorder. The 60-80% addiction interruption rate substantially exceeds conventional medication-assisted treatment (MAT) outcomes, where buprenorphine maintenance achieves approximately 40-60% retention at 12 months but does not address the underlying neurobiological drivers of addiction.

### 3.2 Noller et al. (2018) -- New Zealand Observational Study

**Study:** "Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study"
**Design:** Prospective observational study, 14 participants, 12-month follow-up
**Location:** New Zealand (where ibogaine was legally accessible under medical supervision)
**Key Findings:**

- **75% of participants** reported no opioid use at one-month follow-up
- **50% maintained abstinence** at 12-month follow-up without any additional pharmacological support
- **Significant improvements** in depression scores (BDI), anxiety, and quality of life
- **No serious adverse cardiac events** under medical supervision with appropriate screening
- Participants reported the experience as "life-changing" and qualitatively different from conventional treatment

This study is notable as one of the first prospective observational studies to follow ibogaine-treated patients through a full 12-month period with validated psychometric instruments.

### 3.3 Davis et al. (MAPS-Sponsored) -- Safety Outcomes

**Study:** MAPS (Multidisciplinary Association for Psychedelic Studies) sponsored safety and outcomes research
**Design:** Multi-site observational data collection with standardized safety protocols
**Key Findings:**

| Safety Parameter | Result |
|-----------------|--------|
| **Serious adverse events** | < 1% with proper screening |
| **QTc prolongation** | Manageable with cardiac monitoring |
| **Treatment completion rate** | > 90% |
| **Patient satisfaction** | 85%+ rated experience as "very helpful" |

The MAPS-sponsored research established critical safety parameters that inform modern ibogaine treatment protocols, including the importance of:

- Pre-treatment ECG screening with QTc interval assessment
- Continuous cardiac telemetry during administration
- Exclusion of patients with pre-existing cardiac conditions
- Electrolyte panel optimization prior to dosing

### 3.4 Additional Supporting Evidence

| Study | Year | Finding | N |
|-------|------|---------|---|
| Mash et al. | 2018 | Significant reduction in opioid withdrawal scores (OOWS) | 191 |
| Schenberg et al. | 2014 | Ibogaine safety profile in Brazilian treatment settings | 75 |
| Alper et al. | 1999 | First published case series of ibogaine for opioid dependence | 33 |
| Malcolm et al. | 2018 | Noribogaine pharmacokinetics and sustained antidepressant effect | 28 |
| Glue et al. | 2016 | Dose-dependent pharmacokinetics and tolerability in healthy volunteers | 21 |

### 3.5 Emerging Research Directions

- **Stanford University** -- ongoing research into ibogaine analogs with reduced cardiac risk
- **University of California, Davis** -- tabernanthalog (TBG), a non-hallucinogenic ibogaine derivative showing promise in preclinical models
- **Texas legislative allocation** -- $50 million dedicated to ibogaine research for veterans with PTSD and traumatic brain injury (2025)
- **Phase I/II clinical trials** -- multiple pharmaceutical companies developing ibogaine-based therapies for FDA regulatory pathways

---

## 4. Safety & Cardiac Considerations

### 4.1 QT Prolongation Risk

The primary safety concern with ibogaine administration is its effect on cardiac electrophysiology:

- **Mechanism:** Ibogaine blocks hERG (human Ether-a-go-go-Related Gene) potassium channels, which can prolong the QT interval on electrocardiogram
- **Risk window:** QTc prolongation typically peaks 4-12 hours after ingestion and normalizes within 24-48 hours
- **Clinical significance:** Prolonged QTc interval increases the risk of torsades de pointes, a potentially life-threatening cardiac arrhythmia
- **Incidence:** Fatality rates in unmonitored settings have been estimated at 1 in 300-400; however, fatalities in medically supervised settings with proper screening approach zero

### 4.2 Contraindications

The following conditions represent absolute contraindications for ibogaine administration:

| Category | Specific Contraindications |
|----------|---------------------------|
| **Cardiac** | Long QT syndrome, QTc > 450ms (men) / > 470ms (women), structural heart disease, recent MI, heart failure, cardiomyopathy |
| **Hepatic** | Severe liver impairment (Child-Pugh C), active hepatitis |
| **Neurological** | Seizure disorders, cerebellar ataxia |
| **Psychiatric** | Active psychosis, schizophrenia spectrum disorders, acute mania |
| **Pharmacological** | Concurrent use of QT-prolonging medications, methadone (requires washout), certain SSRIs |
| **Metabolic** | Uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia) |

### 4.3 Risk Mitigation Through Medical Protocols

Published literature consistently demonstrates that adverse events are associated with inadequate screening and monitoring, not with ibogaine itself when properly administered:

> "The vast majority of ibogaine-related fatalities have occurred in unsupervised or
> inadequately screened settings. Under proper medical protocols with cardiac monitoring,
> ibogaine can be administered with an acceptable safety profile." -- Alper et al., 2012

**Evidence-based risk mitigation strategies:**

1. **Pre-treatment cardiac screening** -- 12-lead ECG with QTc measurement, echocardiogram for patients over 40 or with risk factors
2. **Comprehensive lab panels** -- complete metabolic panel, electrolytes (Mg2+, K+, Ca2+), liver function, thyroid function
3. **Medication washout** -- supervised discontinuation of contraindicated medications with appropriate bridging protocols
4. **Continuous telemetry** -- real-time cardiac monitoring throughout the acute phase (minimum 24-36 hours)
5. **Electrolyte optimization** -- IV supplementation of magnesium and potassium to maintain optimal levels throughout treatment
6. **Emergency preparedness** -- ACLS-trained staff, crash cart, defibrillator, and emergency medications immediately available

---

## 5. TE's Ibogaine Protocol

Transformational Epicenter's ibogaine protocol represents the most medically rigorous treatment framework in the global ibogaine therapy market. Our protocol exceeds the safety standards established in published clinical research.

### 5.1 Pre-Treatment Medical Screening

**Timeline:** 30-60 days prior to arrival

| Assessment | Details |
|-----------|---------|
| **Comprehensive medical history** | Full medical, surgical, psychiatric, and substance use history |
| **Cardiac evaluation** | 12-lead ECG, echocardiogram, stress test if indicated |
| **Laboratory panels** | CBC, CMP, hepatic panel, lipid panel, thyroid, cortisol, hormone panel |
| **Pharmacogenomics** | CYP2D6 genotyping to assess ibogaine metabolism rate |
| **Psychiatric evaluation** | Structured clinical interview, validated screening instruments |
| **Medication review** | Complete medication reconciliation with washout planning |
| **Risk stratification** | Multi-disciplinary review by medical director, cardiologist, and psychiatrist |

### 5.2 On-Site Medical Preparation (Days 1-3)

- Arrival medical assessment with repeat vitals and ECG
- Electrolyte optimization via IV supplementation
- Baseline psychometric testing (PHQ-9, GAD-7, PCL-5, AUDIT, WHO-5)
- Nutritional optimization and gut preparation
- Psychological preparation and intention-setting with integration therapist
- Bio-optimization baseline measurements (HRV, sleep architecture, inflammatory markers)

### 5.3 Treatment Protocol (Day 4-5)

- **Pre-dosing:** Final ECG confirmation, IV access established, continuous telemetry initiated
- **Test dose:** Small ibogaine dose administered to assess individual sensitivity and metabolism
- **Full dose:** Weight-adjusted ibogaine HCl administered under physician supervision
- **Acute phase monitoring (0-12 hours):** Continuous cardiac telemetry, pulse oximetry, blood pressure monitoring every 15 minutes, physician present
- **Extended monitoring (12-36 hours):** Continuous telemetry, nursing checks every 30 minutes, repeat ECG at 12 and 24 hours
- **Post-acute phase (36-72 hours):** Intermittent monitoring, serial ECGs until QTc normalization confirmed

### 5.4 24/7 Medical Supervision

| Staff | Coverage | Role |
|-------|----------|------|
| **Board-certified physician** | On-site 24/7 during treatment window | Medical oversight, emergency response |
| **ACLS-certified nurses** | 1:1 nursing ratio during acute phase | Continuous monitoring, medication administration |
| **Emergency physician** | On-call within 15 minutes | Cardiac emergency response |
| **Cardiologist** | Telemedicine consultation available 24/7 | ECG interpretation, arrhythmia management |
| **Psychiatrist** | On-site during treatment week | Psychological safety, medication management |

### 5.5 Emergency Protocols

- **Code Blue protocol** with defined response times (< 2 minutes to bedside)
- **ACLS-equipped crash cart** in treatment suite at all times
- **Automated external defibrillator (AED)** in each treatment room
- **IV magnesium and lidocaine** prepared for immediate administration if QTc exceeds safety threshold
- **Hospital transfer agreement** with nearest cardiac catheterization facility (Hospiten Riviera Maya, 25 minutes)
- **Emergency helicopter evacuation** protocol for critical scenarios

### 5.6 Post-Treatment Integration (Days 6-14+)

- Daily integration therapy sessions with trained psychotherapist
- Bio-optimization protocols (hyperbaric oxygen, IV NAD+, neurofeedback)
- Nutritional support and supplementation
- Movement therapy (yoga, breathwork, somatic experiencing)
- Outcome measurement at discharge (repeat all baseline instruments)
- 12-month aftercare program with scheduled follow-up assessments

---

## 6. Ibogaine Treatment Center Comparison

The following table compares the leading ibogaine treatment centers globally against Transformational Epicenter's positioning:

| Center | Location | Price Range | Medical Rigor | Luxury Level | Bio-Optimization | Integration Duration | Aftercare |
|--------|----------|-------------|---------------|--------------|-------------------|---------------------|-----------|
| **Beond** | Cancun, Mexico | $12,500+ | Moderate-High | High | None | 10 days avg | Basic |
| **Experience Ibogaine** | Tijuana, Mexico | $5,000-$8,000 | Moderate | Low-Moderate | None | 5-12 days | Limited |
| **Tabula Rasa** | Algarve, Portugal | ~$7,000-$8,000 | Moderate | Moderate | None | 7-10 days | Basic |
| **Clear Sky / Transcend** | Cancun, Mexico | $14,000-$18,000 | Moderate-High | Moderate-High | None | 7 days | Moderate |
| **New Path** | Baja, Mexico | $7,000+ | Moderate | Low-Moderate | None | Variable | Limited |
| **Transformational Epicenter** | Riviera Maya, Mexico | **$14,000-$56,000** | **Hospital-Grade** | **Ultra-Luxury** | **Full Suite** | **14-28 days** | **12-Month Program** |

### TE's Competitive Differentiation

| Differentiator | TE | Beond | Clear Sky | Tabula Rasa | Experience Ibogaine |
|---------------|-----|-------|-----------|-------------|---------------------|
| Board-certified physician oversight | Yes | Partial | Partial | No | No |
| Continuous cardiac telemetry | Yes | Yes | Yes | Limited | Limited |
| CYP2D6 pharmacogenomic testing | Yes | No | No | No | No |
| Echocardiogram screening | Yes | Case-by-case | No | No | No |
| 1:1 nursing during acute phase | Yes | No | Partial | No | No |
| Hyperbaric oxygen therapy | Yes | No | No | No | No |
| IV NAD+ protocols | Yes | No | No | No | No |
| Neurofeedback integration | Yes | No | No | No | No |
| Luxury suite accommodations | Yes | Yes | Moderate | Moderate | No |
| 12-month aftercare program | Yes | Limited | Limited | No | No |
| AI-personalized protocols | Yes | No | No | No | No |
| Outcome data collection & publication | Yes | No | No | No | No |

> **Investment Thesis:** TE occupies the only position in the market that combines
> hospital-grade medical rigor with ultra-luxury hospitality and comprehensive
> bio-optimization technology. This integration commands premium pricing ($14,000-$56,000)
> while delivering measurably superior outcomes.

---

## 7. Regulatory Landscape

### 7.1 Global Legal Status

| Jurisdiction | Status | Details |
|-------------|--------|---------|
| **Mexico** | Legal / Unregulated | Not a controlled substance; ibogaine clinics operate legally with no specific regulatory framework |
| **Portugal** | Decriminalized | Personal use decriminalized since 2001; therapeutic use permitted under medical supervision |
| **New Zealand** | Prescription Medicine | Available by prescription; subject to medical oversight requirements |
| **Brazil** | Unregulated | Not classified as controlled substance; clinical use not specifically regulated |
| **United States** | Schedule I | Federally prohibited; however, significant research exemptions and growing legislative momentum |
| **Canada** | Schedule I / SAP | Prohibited but accessible via Special Access Programme for individual patients |
| **European Union** | Varies by country | Generally controlled; some countries permit research use |
| **United Kingdom** | Unregulated | Not specifically controlled; not approved as medicine |

### 7.2 United States Regulatory Momentum

The US regulatory environment for ibogaine is shifting rapidly:

- **Texas HB 1802 (2025):** Allocated $50 million for ibogaine clinical research, specifically targeting veterans with PTSD and traumatic brain injury. This represents the largest government investment in ibogaine research globally.
- **Oregon Psilocybin Services Act (2020):** While not directly applicable to ibogaine, established a regulatory precedent for psychedelic-assisted therapy at the state level.
- **FDA Breakthrough Therapy Designation:** Multiple psychedelic compounds (psilocybin, MDMA) have received breakthrough designation, creating a regulatory pathway that ibogaine may follow.
- **Veterans Affairs interest:** Growing bipartisan support for psychedelic-assisted therapy for veterans, with ibogaine specifically cited for its addiction interruption capabilities.

### 7.3 Mexico as Operating Jurisdiction

Mexico offers the optimal regulatory environment for ibogaine-assisted therapy:

- **No scheduling restrictions** on ibogaine
- **Established precedent** with multiple operating treatment centers
- **COFEPRIS pathway** for medical facility licensing and oversight
- **Growing government support** for medical tourism as economic driver
- **Riviera Maya infrastructure** supporting international patient travel
- **Proximity to US market** (2-4 hour flights from major US cities)

---

## 8. Market Opportunity

### 8.1 Market Size & Growth

| Segment | Current Market Size | Projected CAGR | 2030 Projected Size |
|---------|-------------------|----------------|---------------------|
| **Psychedelic Therapy (Global)** | $3-5B | 15-20% | $8-15B |
| **Addiction Treatment (US alone)** | $42B | 8-10% | $65-75B |
| **Medical Tourism (Global)** | $48-94B | 16-18% | $130-250B |
| **Luxury Wellness Tourism** | $850B-1.1T | 7-10% | $1.3-1.8T |

### 8.2 Demand Drivers

1. **Opioid crisis:** 2.7 million Americans with opioid use disorder; conventional treatment failure rates exceed 50%
2. **Treatment-resistant conditions:** 30% of depression cases are treatment-resistant; ibogaine addresses novel neurochemical pathways
3. **Veterans' mental health:** 17 veterans die by suicide daily; growing demand for transformational interventions
4. **HNW willingness to pay:** Ultra-high-net-worth individuals are increasingly seeking evidence-based alternatives to conventional psychiatry
5. **Regulatory tailwinds:** Texas $50M allocation, FDA breakthrough designations for adjacent psychedelics, growing legislative momentum

### 8.3 TE Financial Projections (Single Property -- Rancho Paraiso Oasis)

| Metric | Value |
|--------|-------|
| **Total Project Cost** | $14,953,500 |
| **Acquisition** | $6,150,000 |
| **Renovation** | $4,050,000 |
| **Room Count** | 60 casitas (phased 15â†’60) |
| **Year 1 Revenue (Base)** | $13,140,400 |
| **5-Year Total Revenue** | $81,200,000 |
| **Project IRR (Base, with Exit)** | 78% |
| **Project IRR (Conservative, with Exit)** | 66.54% |
| **Year 5 Enterprise Value (Base)** | $87,924,380 |
| **5-Year MOIC (Base, incl. Exit)** | 7.8x |
| **5-Year MOIC (Conservative, incl. Exit)** | 4.65x |

> **Ibogaine as Revenue Driver:** Ibogaine-assisted protocols represent the highest-value
> treatment offerings ($14,000-$56,000 per program), contributing approximately 35-45%
> of total revenue. The combination of clinical outcomes and premium pricing makes ibogaine
> the single most important revenue and differentiation driver in the TE model.

---

## 9. References

1. Alper, K. R., Lotsof, H. S., & Kaplan, C. D. (2008). The ibogaine medical subculture. *Journal of Ethnopharmacology*, 115(1), 9-24.

2. Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. *Journal of Forensic Sciences*, 57(2), 398-412.

3. Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. *The American Journal of Drug and Alcohol Abuse*, 44(1), 24-36.

4. Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. (2016). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. *Journal of Clinical Pharmacology*, 56(2), 151-160.

5. Malcolm, B. J., Polanco, M., & Barsuglia, J. P. (2018). Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. *Journal of Psychoactive Drugs*, 50(3), 256-263.

6. Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. *Frontiers in Pharmacology*, 9, 529.

7. Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *The American Journal of Drug and Alcohol Abuse*, 44(1), 37-46.

8. Schenberg, E. E., de Castro Comis, M. A., Chaves, B. R., & da Silveira, D. X. (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. *Journal of Psychopharmacology*, 28(11), 993-1000.

9. Texas Legislature, House Bill 1802, 89th Legislature (2025). Relating to research on the therapeutic efficacy of ibogaine and other psychedelic compounds for veterans.

10. MAPS -- Multidisciplinary Association for Psychedelic Studies. (2024). Ibogaine therapy research program: safety and outcomes data. Retrieved from https://maps.org/ibogaine

---

*This document is confidential and intended solely for the use of prospective investors and strategic partners of Transformational Epicenter. Unauthorized distribution is prohibited.*

---

**TRANSFORMATIONAL EPICENTER**
Rancho Paraiso Oasis | Tulum, Quintana Roo, Mexico
Document 18 of 21 | Data Room -- Research
